Cargando…

Clinical and pathological features associated with circulating tumor DNA content in real‐world patients with metastatic prostate cancer

BACKGROUND: Liquid biopsy is a powerful tool that can enable treatment decisions for metastatic prostate cancer patients with difficult‐to‐biopsy tumors. However, the detection of genomic alterations via liquid biopsy is limited by the fraction (tumor fraction [TF]) of circulating tumor DNA (ctDNA)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Antonarakis, Emmanuel S., Tierno, Marni, Fisher, Virginia, Tukachinsky, Hanna, Alexander, Sonja, Hamdani, Omar, Hiemenz, Matthew C., Huang, Richard S.P., Oxnard, Geoffrey R., Graf, Ryon P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314037/ https://www.ncbi.nlm.nih.gov/pubmed/35286728 http://dx.doi.org/10.1002/pros.24331

Ejemplares similares

Biology and Targetability of the Extended Spectrum of PIK3CA Mutations Detected in Breast Carcinoma
por: Rugo, Hope S., et al.
Publicado: (2023)

Real-World Comprehensive Genomic Profiling Success Rates in Tissue and Liquid Prostate Carcinoma Specimens
por: Hiemenz, Matthew C, et al.
Publicado: (2022)

Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer
por: Graf, Ryon P., et al.
Publicado: (2022)

BRAF V600E and RNF43 Co-mutations Predict Patient Outcomes with Targeted Therapies in Real-World Cases of Colorectal Cancer
por: Quintanilha, Julia C F, et al.
Publicado: (2023)

Real-world Validation of TMB and Microsatellite Instability as Predictive Biomarkers of Immune Checkpoint Inhibitor Effectiveness in Advanced Gastroesophageal Cancer
por: Graf, Ryon P., et al.
Publicado: (2022)

Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting Therapies
por: Zurita, Amado J., et al.
Publicado: (2022)

Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden
por: Quintanilha, Julia C. F., et al.
Publicado: (2023)

Unique Spectrum of Activating BRAF Alterations in Prostate Cancer
por: Chehrazi-Raffle, Alex, et al.
Publicado: (2023)

Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types
por: Maule, Jake G, et al.
Publicado: (2022)

Partial treatment response to capmatinib in MET-amplified metastatic intrahepatic cholangiocarcinoma: case report & review of literature
por: Lefler, Daniel S, et al.
Publicado: (2022)

Mismatch repair–deficient prostate cancer with parenchymal brain metastases treated with immune checkpoint blockade
por: Sena, Laura A., et al.
Publicado: (2021)

Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB
por: He, Jie, et al.
Publicado: (2023)

Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness
por: Quintanilha, Julia C.F., et al.
Publicado: (2023)

Tumor Fraction Correlates With Detection of Actionable Variants Across > 23,000 Circulating Tumor DNA Samples
por: Husain, Hatim, et al.
Publicado: (2022)

Variable Landscape of PD-L1 Expression in Breast Carcinoma as Detected by the DAKO 22C3 Immunohistochemistry Assay
por: Danziger, Natalie, et al.
Publicado: (2023)

Complementary Roles for Tissue- and Blood-Based Comprehensive Genomic Profiling for Detection of Actionable Driver Alterations in Advanced NSCLC
por: Schwartzberg, Lee S., et al.
Publicado: (2022)

Potential pathogenic germline variant reporting from tumor comprehensive genomic profiling complements classic approaches to germline testing
por: Tung, Nadine, et al.
Publicado: (2023)

Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis
por: Huang, Richard S P, et al.
Publicado: (2023)

Circulating tumor DNA analysis in the era of precision oncology
por: Said, Rabih, et al.
Publicado: (2020)

Clinical Evaluation of Abiraterone in the Treatment of Metastatic Prostate Cancer
por: Goyal, Jatinder, et al.
Publicado: (2013)

PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date
por: Nizialek, Emily, et al.
Publicado: (2020)

Development of an immunofluorescent AR-V7 circulating tumor cell assay – A blood-based test for men with metastatic prostate cancer
por: Lu, David, et al.
Publicado: (2020)

Androgen receptor expression on circulating tumor cells in metastatic breast cancer
por: Fujii, Takeo, et al.
Publicado: (2017)

Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer
por: Boudadi, Karim, et al.
Publicado: (2016)

Rucaparib for metastatic castration-resistant prostate cancer: did TRITON3 deliver a trifecta?
por: Elias, Roy, et al.
Publicado: (2023)

Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer
por: Paller, Channing J, et al.
Publicado: (2011)

Genomic landscape of 891 RET fusions detected across diverse solid tumor types
por: Parimi, Vamsi, et al.
Publicado: (2023)

A mechanism for vertebrate Hedgehog signaling: recruitment to cilia and dissociation of SuFu–Gli protein complexes
por: Tukachinsky, Hanna, et al.
Publicado: (2010)

Analytical Validation and Capabilities of the Epic CTC Platform: Enrichment-Free Circulating Tumour Cell Detection and Characterization
por: Werner, Shannon L., et al.
Publicado: (2015)

Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients
por: Anantharaman, Archana, et al.
Publicado: (2016)

The Influence of Prednisone on the Efficacy of Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer
por: Teply, Benjamin A., et al.
Publicado: (2015)

Metastatic Castration-Resistant Prostate Cancer, Immune Checkpoint Inhibitors, and Beyond
por: Lanka, Sree M., et al.
Publicado: (2023)

A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer
por: Assaf, Zoe June F., et al.
Publicado: (2023)

Cooperation of the ER-shaping proteins atlastin, lunapark, and reticulons to generate a tubular membrane network
por: Wang, Songyu, et al.
Publicado: (2016)

Clinical Utility of Liquid Biopsy to Identify Genomic Heterogeneity and Secondary Cancer Diagnoses: A Case Report
por: Hemenway, Gregory, et al.
Publicado: (2022)

ERBB2 Copy Number as a Quantitative Biomarker for Real-World Outcomes to Anti–Human Epidermal Growth Factor Receptor 2 Therapy in Advanced Gastroesophageal Adenocarcinoma
por: Zhang, Liangliang, et al.
Publicado: (2022)

Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer
por: Pellini, Bruna, et al.
Publicado: (2023)

Association of Copy Number Variation Signature and Survival in Patients With Serous Ovarian Cancer
por: Graf, Ryon P., et al.
Publicado: (2021)

Tumorigenic potential of circulating prostate tumor cells
por: Carvalho, Filipe LF., et al.
Publicado: (2013)

Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study()
por: Reichert, Z. R., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gb723tdcgan8u183fp11v8n4c8